retatrutide glp-1 gip glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide vs. Ozempic

A more recent analysis using cardiovascular outcome trials further indicated no excess risk of either acute pancreatitis [Peto OR 0.89 (95% CI 0.63, 1.27)] or pancreatic cancer [Peto OR 0.84 (95% CI 0.53, 1.35)] with GLP-1RAs vs

Code Availability No custom code was developed for this review article

[Google Scholar] 7.Gleason P.P., Urick B.Y., Marshall L.Z., Friedlander N., Qiu Y., Leslie R.S

Firstly, using the CPRD allowed for the ability to adjust for important potential confounders, including cardiovascular risk factors, microvascular and macrovascular complications, body mass index, and laboratory measures, which are often unavailable in other datasets

Which GLP-1 medications lost BCBS coverage The coverage changes targeted specific medications and specific indications